Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 11.1%

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) rose 11.1% on Thursday . The stock traded as high as $24.34 and last traded at $24.15. Approximately 289,463 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 527,843 shares. The stock had previously closed at $21.73.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Canaccord Genuity Group cut their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a report on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, July 2nd. Finally, William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $64.86.

Arcturus Therapeutics Stock Up 9.3 %

The company has a market capitalization of $639.86 million, a P/E ratio of -6.08 and a beta of 2.64. The company has a 50-day moving average of $29.36 and a two-hundred day moving average of $32.12.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) EPS for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.17. The firm had revenue of $38.01 million for the quarter, compared to analysts’ expectations of $22.12 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. As a group, equities analysts expect that Arcturus Therapeutics Holdings Inc. will post -4.39 EPS for the current fiscal year.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the transaction, the chief operating officer now owns 447,448 shares of the company’s stock, valued at $17,902,394.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC increased its position in shares of Arcturus Therapeutics by 239.8% during the third quarter. AQR Capital Management LLC now owns 172,202 shares of the biotechnology company’s stock valued at $4,400,000 after acquiring an additional 121,526 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Arcturus Therapeutics by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 43,350 shares of the biotechnology company’s stock worth $1,108,000 after purchasing an additional 1,098 shares in the last quarter. ARK Investment Management LLC raised its stake in shares of Arcturus Therapeutics by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock worth $64,564,000 after purchasing an additional 146,141 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Arcturus Therapeutics by 352.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 2,406 shares during the last quarter. Finally, Arizona State Retirement System bought a new position in shares of Arcturus Therapeutics during the fourth quarter valued at $211,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.